Gezie Lemma Derseh, Gelaye Kassahun Alemu, Worku Abebaw Gebeyehu, Ayele Tadesse Awoke, Teshome Destaw Fetene
Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Department of Reproductive Health, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
BMC Res Notes. 2017 Jul 14;10(1):277. doi: 10.1186/s13104-017-2602-0.
CD4 cells are the major targets for human immunodeficiency virus (HIV) and treatment with Antiretroviral Therapy (ART) influences the CD4 cell count of HIV patients. In addition to ART, the time required to reach normal range of CD4 counts (500 cells/mm) can be affected by clinical, socio-demographic, and behavioral factors. This retrospective cohort study was conducted to determine the incidence of having the normal range of CD4 cell counts and factors that affect the time required to reach this normal range among adult HIV patients who initiated into ART.
Data of 4 years were retrospectively retrieved from routinely registered characteristics of 937 ART users enrolled in 2010. Survival time until immunologic recovery and its determinant factors were examined using the frailty model with different parametric distributions alternatively.
Most (80.8%) of the ART attendants had CD4 cell count of 200 cells/mm or less at initiation. The overall incidence rate of immunologic recovery was 12.67 persons per 1000 person-months (95% CI 11.30, 14.20). The dependency of frailties of immunologic recovery by residence was statistically significant (Theta = 0.05, p value = 0.006). Baseline age (Adjusted Hazard Ratio (AHR) = 0.98, 95% CI 0.97, 0.99), baseline CD4 count (AHR = 1.006, 95% CI 1.005, 1.008), and female sex (AHR = 1.34, 95% CI 1.03, 1.73) were significantly associated with shorter survival time for immunologic recovery.
Higher baseline CD4 count, lower baseline age, and female sex were positively associated with the time to immunologic recovery, which also dependent on proximity/residence of ART users. Therefore, further scale up of ART services with due emphasis to patients with low CD4 count at baseline particularly for male and older ART users are recommended to reach the normal range of CD4 count in a shorter time of treatment.
CD4细胞是人类免疫缺陷病毒(HIV)的主要靶细胞,抗逆转录病毒疗法(ART)治疗会影响HIV患者的CD4细胞计数。除ART外,达到CD4计数正常范围(500个细胞/mm³)所需的时间可能受临床、社会人口统计学和行为因素影响。本回顾性队列研究旨在确定开始接受ART治疗的成年HIV患者中CD4细胞计数达到正常范围的发生率以及影响达到该正常范围所需时间的因素。
回顾性检索了2010年登记入组的937名ART使用者的常规登记特征中的4年数据。使用具有不同参数分布的脆弱模型交替检验免疫恢复的生存时间及其决定因素。
大多数(80.8%)接受ART治疗者开始治疗时CD4细胞计数为200个细胞/mm³或更低。免疫恢复的总体发生率为每1000人月12.67人(95%可信区间11.30,14.20)。按居住地划分的免疫恢复脆弱性的依赖性具有统计学意义(Theta = 0.05,p值 = 0.006)。基线年龄(调整后风险比(AHR)= 0.98,95%可信区间0.97,0.99)、基线CD4计数(AHR = 1.006,95%可信区间1.005,1.008)和女性性别(AHR = 1.34,95%可信区间1.03,1.73)与免疫恢复的较短生存时间显著相关。
较高的基线CD4计数、较低的基线年龄和女性性别与免疫恢复时间呈正相关,免疫恢复时间还取决于ART使用者的距离/居住地。因此,建议进一步扩大ART服务规模,尤其要重视基线CD4计数低的患者,特别是男性和年龄较大的ART使用者,以便在较短治疗时间内达到CD4计数正常范围。